Glauconix Changes Name to Humonix

Glauconix Biosciences has changed its name to Humonix Biosciences as the company has expanded beyond glaucoma to technology can support various cell types.

"What began as a specialization in glaucoma therapeutics has become a launchpad for developing new fibrotic and vascular 3D human tissue models," the company stated in a news release. "This move is reflective of a larger breadth of service offerings and a vision to expand the 3D human tissue systems to address other diseases in the body."

Glauconix announced a new retinal vascular dysfunction 3D model proven to express key physiological and biological characteristics. The new model is designed to help along all aspects of the drug development process and expedite drug development by utilizing 3D human tissue, which has greater translatability and quicker turnaround times than other more traditional preclinical testing methods. 

"This is a very exciting time for us as we move closer to our vision to make all fibrotic and vascular diseases treatable. We are making good on our commitment to our customers to relentlessly innovate and create new opportunities for breakthrough therapies to succeed," said Kimberly Southern, Chief Executive Officer, Humonix

"It's a transformational time for Humonix as they expand their industry-leading platform technology to address the significant unmet need in the marketplace for validated fibrotic and vascular 3D tissue models," said Robert Dempsey, Chief Executive Officer, President, AsclepiX Therapeutics, and Humonix Board Member. "I'm excited to continue supporting the company and looking forward to seeing what comes next."